You are here

• Home

• Investor relations

• Latest news collapse

  • 26 July 2010 Advisory Committee Briefing Materials For Brilinta (Ticagrelor) NDA Available On US FDA Web Site

    The US Food and Drug Administration (FDA) today posted briefing materials in advance of 28th July 2010 Cardiovascular and Renal Drugs Advisory Committee (CRDAC) to discuss the New Drug Application (NDA) filed by AstraZeneca for its investigational oral antiplatelet ticagrelor. The proposed trade name for ticagrelor in the US is BRILINTA, pending approval from the FDA.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Annual Information Update

  Annual information update (PDF 84kb)

  Currency Guidance 2010 collapse

  • View 2010 currency guidance

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  Disease area focus

  Review pipeline summary

  Managing your shares collapse

  • Dividend information
  • Shareholder forms
  • Share registration contacts
  • Annual General Meeting
  • FAQs

• Historical sales information

  Historical sales (PDF 1.09 mb)

  Historical sales (XLS 196.4 kb)

  Annual Report 2009 collapse

  • Online annual report
  • Order a printed copy

  Latest presentation collapse

  29 July 2010
  

  • Second quarter and half year results (PDF 336 kb) 

  • Other presentations

  Financial results collapse

  Second quarter and half year results 2010 announced Thursday, 29 July 2010.

  View details of the event

  View financial calendar

  Share price tools collapse

  • Interactive stock charts
  • Share holding calculator
  • Share price look-up
  • Share price history

Not signed in

Page tools

• Print
• Bookmark this page

Share price